Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
FASEB BioAdvances is Scopus-indexed (Q2, CiteScore 3.5), WoS ESCI, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2573-9832Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry, Genetics and Molecular Biology (miscellaneous) | 65 / 144 | 55th | Q2 |
| Physiology | 128 / 196 | 34th | Q3 |
| Cancer Research | 170 / 233 | 27th | Q3 |
| Molecular Medicine | 131 / 179 | 27th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q2, CiteScore 3.5.
FASEB BioAdvances is Q2 in Biochemistry, Genetics and Molecular Biology (miscellaneous) (rank 65 of 144), Q3 in Physiology (rank 128 of 196) and Q3 in Cancer Research (rank 170 of 233), by CiteScore 2025. It is ranked in 4 subject areas in all.
FASEB BioAdvances is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.5, which places it in quartile Q2 at the 55th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.776, quartile Q2, with an H-index of 26.
The publisher lists an article processing charge of about US$2,880 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
FASEB BioAdvances is published by John Wiley and Sons Inc. Its ISSN is 2573-9832.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
FASEB BioAdvances has an h-index of 33 and a 2-year mean of 2.08 citations per paper (OpenAlex). Its Scopus CiteScore is 3.5, quartile Q2. On 2-year citations it ranks #68 of 141 Scopus journals in Biochemistry, Genetics and Molecular Biology (miscellaneous).
FASEB BioAdvances published 98 papers in 2025; its busiest recent year was 2021 with 109. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United States (35.8%), China (23.2%) and Japan (7.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.